SAN
FRANCISCO, Nov. 19, 2024 /PRNewswire/ -- Schubert
Jonckheer & Kolbe LLP advises ImmunityBio, Inc. investors that
the firm is investigating potential legal claims relating to the
company's unsuccessful efforts in 2023 to secure regulatory
approval for its flagship product Anktiva, designed to treat
bladder cancer. Current shareholders are encouraged to contact the
firm.
On June 20, 2024, Judge
Gonzalo P. Curiel of the U.S.
District Court for the Southern District of California issued an order denying in part a
motion to dismiss a class action complaint filed against
ImmunityBio and certain of its executive officers. There, it is
alleged that biotechnology company ImmunityBio intentionally misled
investors between March 2021 and
May 2023 about the prospects of
obtaining U.S. Food and Drug Administration approval for Anktiva by
concealing known recordkeeping, quality control, and sanitation
problems at its contract manufacturer. When the truth was revealed
in May 2023, ImmunityBio's stock fell
55%.
The Schubert firm is investigating potential wrongdoing by
ImmunityBio's officers and directors in connection with these
allegations.
If you own stock in ImmunityBio and want additional
information about your legal rights, please visit our website
at
https://www.classactionlawyers.com/immunitybio.
About Schubert Jonckheer & Kolbe LLP
Schubert Jonckheer & Kolbe represents shareholders,
employees, and consumers in class actions against corporate
defendants, as well as shareholders in derivative actions against
their officers and directors. The firm is based in San Francisco, and with the help of
co-counsel, litigates cases nationwide.
Contact
Dustin L.
Schubert
Schubert Jonckheer & Kolbe LLP
dschubert@schubertlawfirm.com
Tel: (415) 788-4220
View original
content:https://www.prnewswire.com/news-releases/immunitybio-inc-investor-alert-nasdaq-ibrx-schubert-jonckheer--kolbe-llp-investigating-potential-shareholder-claims-against-the-companys-officers-and-directors-for-possible-false-statements-302309637.html
SOURCE Schubert Jonckheer & Kolbe LLP